Fat loss
Survodutide
Boehringer Ingelheim's GLP-1/glucagon dual agonist in Phase 3, showing 17-22% weight loss with a cardiovascular outcomes trial underway.
- Full name
- BI 456906 (dual glucagon and GLP-1 receptor agonist)
- Also known as
- BI 456906, GLP-1/GCGR dual agonist
- Regulatory status
- Investigational (Phase 3) | Cardiovascular outcomes trial ongoing
Origin
Developed by Boehringer Ingelheim as a once-weekly subcutaneous GLP-1/glucagon receptor dual agonist. In Phase 3 following positive Phase 2 dose-finding trials in obesity, with multiple regional Phase 3 trials active including a dedicated cardiovascular outcomes trial.
Mechanism
Selective dual agonist of GLP-1R and GCGR with balanced activity at both, combining appetite suppression with hepatic lipogenesis inhibition and higher energy expenditure. Preclinical and early clinical data suggest it preferentially reduces visceral and hepatic adiposity.
Research summary
Evidence
Phase 2/3 data show survodutide 3.6-4.8 mg produces 17-22% body weight reductions over 52 weeks, with reported liver-fat reductions of 60-80% in some cohorts. Heart-rate elevation is observed and under formal cardiovascular evaluation. GI adverse events are dose-limiting but typically mild-to-moderate. Evidence is limited to 52-76 weeks of exposure.
Evidence tier: Investigational (Phase 3) — see the methodology note for how this is assessed.
Citations
Reported benefits
- weight loss (17-22% body weight reduction)
- improved glycemic control
- preferential visceral and liver-fat reduction
- potential cardioprotection (under investigation)
Dosing protocols reported in the literature & community
These are protocols reported by compounding pharmacies, published trials, or self-experimentation communities — not a prescription. Start low, especially for anything new.
| Route | Reported protocol |
|---|---|
| Subcutaneous injection | Once-weekly: gradual escalation to maintenance at 3.6 or 4.8 mg over 4-8 weeks. |
Side effects
- nausea
- vomiting
- diarrhea
- constipation
- fatigue
- increased heart rate
- potential QTc prolongation (under investigation)
Safety notes
Community & reddit notes (anecdotal — not clinical evidence)
Biohacker access is limited since it's a Phase 3 drug. Scattered anecdotal trial-participant reports suggest efficacy similar to or better than mazdutide with slightly better liver-fat reduction.
Related peptides
Mixing compatibility
Pulled from a community-charted mixing-compatibility reference (anecdotal, clinic-use, and community-reported signals) — not a safety guarantee. Verify independently before combining anything.